Reneuron (RENE.L) is a stem cell research company whose focus is on therapies targeting areas of poorly met medical need, including peripheral arterial disease, stroke, and retinal diseases. RENE is currently testing the effects of neural stem cells on spines for neuroregeneration, and is testing the use of fetal stem cells on stroke patients.
A UK company, used as a scientific comparable due to status of trials and disease state.
December 3, 2015
RegMed’s close: stocks sold-off further into negative territory
December 1, 2015
RegMed’s close: weakness trumps expectation after a week of ups
November 30, 2015
RegMed’s close: The sector can’t hide from a few things …
November 27, 2015
RegMed’s close: what’s more dangerous than the lesson of price swing bubbles?
November 25, 2015
RegMed’s close: thanks for a up/positive close day in a hit or miss sector
November 24, 2015
RegMed’s close: another knee- jerk reaction
November 23, 2015
RegMed’s close: I always worry about spikes in pricing and advance/decline lines
November 23, 2015
Lower open expected. RegMed’s pre-open, the sector has spiked higher as we await the next inversion
November 20, 2015
RegMed’s close: week-over-week variations are causing investor inertia and speculator devilment
November 19, 2015
Higher open is expected. RegMed’s pre-open, it’s very much a whipsaw sector
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.